ViaCyte, Inc. Announces FDA Acceptance of IND to Commence Clinical Trial of … – MarketWatch
|
ViaCyte, Inc. Announces FDA Acceptance of IND to Commence Clinical Trial of …
MarketWatch Instrumental in our ability to achieve this milestone are JDRF, the leading global organization focused on type 1 diabetes (T1D) research, and the California Institute for Regenerative Medicine, a leading organization focused on advancing stem cell … |
